Abstract 1570
Background
Systemic chemotherapy (SC) has a negative effect on ovarian functions. The aim of this study is to investigate the effect of SC on anti-müllerian hormone (AMH) levels, antral follicle counts (AFC) and ovarian volumes (MOV) in patients with BC.
Methods
The demographic, clinical and pathological features of premenopausal breast cancer (BC) patients who were operated in the Istanbul Florence Nightingale Hospital were recorded. AMH levels, AFC and MOV measurements were performed before and after adjuvant SC in 3-month periods. The patients who did not have menstruel cycles for 6 months or longer had been classified as chemotherapy induced amenorrhea (CIA). The effects of different chemotherapy regimens on AMH, AFC and MOV in terms menstruel cycles resumption and CIA were investigated.
Results
Seventy one patients were eligible for the study, and median age of them was 38 years (ranged from 23 to 51 years). Median follow-up was 37 months (ranged from 20 to 51 months), CIA developed in 62% of patients. AMH, AFC, and MOV significantly decreased one year after SC (p < 0.0001). AMH before chemotherapy (median: 1,520 vs 0,755, p = 0.001), at the end of first year (median: 0,073 vs 0,010 ng/ml, p = 0.030) and pre-treatment AFC (median12 vs 4,50, p = 0.026) was lower in patients with CIA comparing those without CIA. In multivariate logistic regression analysis, AMH levels (OR:0.273, 95%: 0.102 – 0.733, p = 0.010) and AFC (OR: 1,180, 95% CI; 1,016-1,369, p = 0.030) before SC were the most valuable and earliest factors to predict CIA. There were no significant relationships between age of the patients (≤30vs>30 ), BMI (30vs> 30), SC regimen and number of cycles (4 vs > 4) and CIA (p > 0.05).Table:
254P muitivariet analyses with logistic regrettion for CIA
| UNIVARIET | MULTIVARIET | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | ||||||
| ER | 0,19 | 0,038 | - | 0,891 | 0,035 | 0,002 | 0,000 | - 0,111 | 0,002 |
| HER 2 | 0.80 | 0,435 | - | 2,936 | 1,130 | ||||
| ALND PERFORMED | 1,75 | 0,653 | - | 4,702 | 0,265 | ||||
| AMH-1 | 0,64 | 0,454 | - | 0,914 | 0,014 | 0,273 | 0,102 | - 0,733 | 0,010 |
| AMH-5 | 0,23 | 0,063 | - | 0,812 | 0,023 | 0,009 | 0,000 | - 0,754 | 0,037 |
| AFC-1 | 0,87 | 0,780 | - | 0,961 | 0,007 | 0,735 | 0,572 | - 0,944 | 0,016 |
| AFC-5 | 0,93 | 0,741 | - | 1,165 | 0,527 | ||||
| MOV-1 | 1,00 | 0,987 | - | 1,021 | 0,686 | ||||
| MOV-5 | 0,98 | 0,854 | - | 1,158 | 0,790 | ||||
| TAXANE/W&İTHOUTTAXANE | 0,71 | 0,267 | - | 1,910 | 0,503 | ||||
| TC/AC | 0,85 | 0,209 | - | 3,491 | 0,825 | ||||
| AGE 35 | 4,66 | 1,613 | - | 13,498 | 0,004 | ||||
| CHEMONUMBER | 0,24 | 0,080 | - | 0,766 | 0,017 | ||||
| BMI 25 | 2,57 | 0,929 | - | 7,118 | 0,069 |
Conclusions
SC significantly decreases AMH and AFC values independently of chemotherapeutic agents in patients with BC. The low AMH levels and less AFC before SC may predict CIA.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
İstanbul Demiroğlu Bilim University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5458 - Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen.
Presenter: Philippe Ruszniewski
Session: Poster Display session 2
Resources:
Abstract
1234 - Analysis of PD-1/PD-L1 blockade biomarker and immune infiltrates in Gastroenteropancreatic neuroendocrine carcinoma
Presenter: Jia Zhang Xing
Session: Poster Display session 2
Resources:
Abstract
1517 - Diabetes Is Associated With Pancreatic Neuroendocrine Tumors Growth and Metastasis
Presenter: Zhiyao Fan
Session: Poster Display session 2
Resources:
Abstract
2145 - Investigation of the reclassification of G1/G2 pancreatic neuroendocrine neoplasms by WHO 2017 classification
Presenter: Takahiro Yokose
Session: Poster Display session 2
Resources:
Abstract
3134 - Treatment with somatostatin analogues after radiopeptide therapy
Presenter: Daria Handkiewicz Junak
Session: Poster Display session 2
Resources:
Abstract
2191 - Safety and Tolerability of Surufatinib in Western Patients with Solid Tumors
Presenter: Erika Hamilton
Session: Poster Display session 2
Resources:
Abstract
3253 - The impact of tumour absorbed dosimetry with survival outcomes after peptide receptor radionuclide therapy in metastatic neuroendocrine tumours.
Presenter: Rahul Ladwa
Session: Poster Display session 2
Resources:
Abstract
3581 - Opportunist and Serious Infections in Patients with Neuroendocrine Tumors Treated With Everolimus: A Multicenter Study of Real World Patients
Presenter: Carine Mauro
Session: Poster Display session 2
Resources:
Abstract
5374 - Establishment of Prognostic Nomogram Based on the Metastatic Lymph Nodes Ratio for Patients with Gastric Neuroendocrine Tumour
Presenter: yaobin lin
Session: Poster Display session 2
Resources:
Abstract
3951 - Neutrophil-lymphocyte ratio as an independent predictive factor in Neuroendocrine Neoplasms
Presenter: Sofia Ferreira
Session: Poster Display session 2
Resources:
Abstract